Immune-Onc Therapeutics Inc., based in the U.S., is entering into a collaboration with Roche (SWX: ROG) to conduct a Phase Ib/II clinical study evaluating its LILRB2 (ILT4) monoclonal antibody (mAb) IO-108 in combination with Roche’s PD-L1 mAb atezolizumab and VEGF mAb bevacizumab. This study aims to target first-line localized advanced, metastatic, and/or unresectable hepatocellular carcinoma (HCC).
Led by Roche, the study will evaluate the safety, efficacy, and pharmacodynamics of the combination therapy compared to the standard treatment of atezolizumab combined with bevacizumab.
Results from a Phase I dose escalation study, presented at the 2023 American Association for Cancer Research (AACR) annual meeting, demonstrated a favorable safety profile for IO-108 across various cancer types, revealing positive outcomes both as a monotherapy and in conjunction with a PD-1 inhibitor. A global randomized Phase Ib/II study is currently in progress, exploring the potential of IO-108 when paired with atezolizumab and bevacizumab for first-line treatment of HCC.- Flcube.com
